| Title: |
MOG IgG3-Subclass Antibodies in MOG-Associated Disease: Insights From a Pediatric Case With IgG1 Deficiency and Literature Review |
| Authors: |
Fetta A.; Conti F.; Lopalco A.; Corsini C.; Moratti M.; Morelli L.; Ricciardiello F.; Toni F.; Lanari M.; Liguori R.; Cordelli D. M.; Giannoccaro M. P. |
| Contributors: |
Fetta, A.; Conti, F.; Lopalco, A.; Corsini, C.; Moratti, M.; Morelli, L.; Ricciardiello, F.; Toni, F.; Lanari, M.; Liguori, R.; Cordelli, D. M.; Giannoccaro, M. P. |
| Publication Year: |
2026 |
| Collection: |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: |
MOGAD; Neuroimmunology; pediatric neurology; Autoimmune neurological disorders |
| Description: |
ObjectivesThis report details a pediatric case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) characterized by isolated MOG-IgG3 positivity and IgG1 deficiency, highlighting a unique serologic profile and exploring its immunologic significance. In addition, a review of MOGAD cases with isolated MOG-IgG3 antibodies is included.MethodsA 12-year-old boy presenting with a progressive neurologic syndrome underwent clinical, radiologic, and laboratory evaluation.ResultsMRI showed extensive brain and spinal lesions. MOG-IgG3 antibodies were identified in serum and CSF by live cell-based assay, while other MOG-IgG subclasses were not detected. Serum IgG1 was low at baseline and throughout follow-up. First-line immunotherapy treatment led to significant improvement, with no relapses at 2-year follow-up.DiscussionThis case highlights the potential role of subclinical IgG1 deficiency in shaping the predominance or selective detection of MOG-IgG3 in MOGAD. While most MOG antibodies are predominantly of the IgG1 isotype, our review identified a few cases with isolated MOG-IgG3 antibodies. A possible contribution to pathogenesis cannot be excluded, and the patient's inability to produce a balanced IgG subclass profile could have favored a sustained IgG3 response. Larger studies are needed to clarify the clinical significance of MOG-IgG3 in MOGAD. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41406406; info:eu-repo/semantics/altIdentifier/wos/WOS:001641687800001; volume:13; issue:1; firstpage:1; lastpage:6; numberofpages:6; journal:NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION; https://hdl.handle.net/11585/1039290 |
| DOI: |
10.1212/NXI.0000000000200523 |
| Availability: |
https://hdl.handle.net/11585/1039290; https://doi.org/10.1212/NXI.0000000000200523; https://www.neurology.org/doi/10.1212/NXI.0000000000200523 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND) ; license uri:iris.PUB17 |
| Accession Number: |
edsbas.659F6687 |
| Database: |
BASE |